Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IL6 | P05231 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918639 | 0.84 | ERN1 (0.41) | ERN1PIM1PIM3NFKB1MEN1 | |
| SCHEMBL30991108 | 0.81 | ERN1 (0.43) | ERN1PIM1PIM3NFKB1MEN1 | |
| SCHEMBL6853771 | 0.81 | NFKB1 (0.44) | ERN1PIM1PIM3NFKB1MEN1 | |
| SCHEMBL472405 | 0.81 | KIF11 (0.42) | ERN1PIM1PIM3NFKB1MEN1 | |
| SCHEMBL7526291 | 0.81 | NFE2L2 (0.40) | ERN1PIM1PIM3LMNATDP1 | |
| SCHEMBL4947084 | 0.81 | ERN1 (0.40) | ERN1MEN1LMNAKMT2AKIF11 | |
| SCHEMBL67207 | 0.80 | NFKB1 (0.57) | PIM1PIM3NFKB1MEN1LMNA | |
| SCHEMBL29417728 | 0.80 | NFKB1 (0.57) | PIM1PIM3NFKB1MEN1LMNA | |
| SCHEMBL29850578 | 0.79 | ERN1 (0.42) | ERN1PIM1PIM3NFKB1CTSS | |
| SCHEMBL6853865 | 0.79 | KMT2A (0.58) | ERN1MEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970287-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-01 | — | — | EP | claimed |
| EP-1472215-A4 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-05-09 | — | — | EP | claimed |
| US-20060084176-A1 | Detection of uronium salts | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-04-20 | — | — | US | claimed |
| US-6949574-B2 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| EP-1472215-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | SIT SING-YUEN (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003065989-A2 | (OXIME)CARBAMOYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-14 | — | — | WO | claimed |
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-0657432-A1 | Phenyl-substituted 1,4-dihydropyridines with cerebral activity | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
| US-5041683-A | Nuclear-fluorinated trifluoromethylbenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| EP-0225175-A2 | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof | FISONS plc (GB) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | ERN1 1106/4885PIM1 4738/4885PIM3 4756/4885 |
| US-20030195226-A1 | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors | FAAH, FAAH2, NCEH1 | ERN1 4398/4885PIM1 4636/4885PIM3 4703/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ERN1 1106/4885PIM1 4738/4885PIM3 4756/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | ERN1 1106/4885PIM1 4738/4885PIM3 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.